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Case Report / Caso Clinico   
Cryptogenic organizing pneumonia 
after radiotherapy for breast cancer 
Polmonite organizzativa criptogenetica 
dopo radioterapia per cancro della mammella   
Giorgio Fumagalli, Claudio M. Sanguinetti 
Unità Operativa Complessa di Pneumologia, ACO San Filippo Neri, Roma
ABSTRACT
We report a case of fever, dyspnea, respiratory failure and
migratory, recurrent and bilateral lung opacities 4 months
after radiotherapy and hormone therapy following surgery
for breast cancer. Computerized tomography (CT) scans
showed infiltrates outside the radiation fields.
Bronchoalveolar lavage revealed lymphocytic alveolitis,
whereas laboratory analysis demonstrated a mild systemic
inflammation. Systemic steroids resulted in clinical and radi-
ological improvement, but a disease relapse was evident at
withdrawal of therapy, with definitive clinical and radiological
normalization after a second cycle of therapy. This is a case of
cryptogenic organizing pneumonia (COP) (previously known
as bronchiolitis obliterans organizing pneumonia) primed by
radiotherapy, as in previously reported cases. It is extremely
important to be aware of the possibility of this complication,
in order to optimize radiation and hormone treatment of
breast cancer. 
Keywords: Breast cancer, lung function, radiation-primed COP,
radiotherapy.
RIASSUNTO 
Descriviamo un caso di febbre, dispnea, insufficienza respira-
toria e opacità polmonari migranti, ricorrenti bilateralmente,
insorte 4 mesi dopo radioterapia in una paziente sottoposta a
radioterapia post-chirurgica e in corso di ormonoterapia per
cancro della mammella.
La TAC del torace dimostrava la presenza di infiltrati polmo-
nari al di fuori del campo di irradiazione. Il lavaggio bronco-al-
veolare documentava la presenza di alveolite linfocitaria,
mentre gli esami di laboratorio evidenziavano una modesta
infiammazione sistemica. La somministrazione di corticoste-
roidi ad alte dosi per os determinava un miglioramento clinico
e radiologico, ma la sospensione della terapia steroidea coin-
cideva con una ripresa della malattia. Dopo un secondo ciclo
di terapia si aveva la definitiva normalizzazione del quadro cli-
nico e radiologico. Questo è un caso di polmonite organizzati-
va criptogenetica (precedentemente indicata con il termine di
polmonite organizzativa con bronchiolite obliterante) indotta
dalla radioterapia, così come riportato precedentemente in
altri casi. È molto importante tenere presente la possibilità di
questa complicanza per ottimizzare il trattamento radiotera-
pico e ormonale del cancro della mammella.
Parole chiave: Cancro della mammella, COP indotta da radio-
terapia, funzione respiratoria, radioterapia.
INTRODUCTION
Radiotherapy represents a cornerstone of the treat-
ment of breast cancer. In the past, the less advanced
technology was the cause of severe damage to sur-
rounding tissues in the breast, lung and chest wall.
Today the planning of irradiation fields guarantees
the near total absence of collateral effects, in par-
ticular pneumonia and fibrosis induced by radio-
therapy [1].
Radiation-induced pneumonia occurs classically 4
to 12 weeks after the radiotherapy and is character-
ized by fever, dry cough, dyspnea and alveolar
opacities confined to the treatment port [2].
However, bilateral lymphocytic alveolitis develops
in both lungs after strictly unilateral breast irradia-
tion and it presents with the histological, radiologi-
cal and clinical pattern of bronchiolitis obliterans
organizing pneumonia (BOOP), now currently
defined as cryptogenic organizing pneumonia
(COP) [3]. 
COP is a distinct clinico-pathological entity in the
wide family of pulmonary fibrosis, and is character-
ized by patchy and often migratory peripheral air
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space infiltrates on chest radiography [4,5]. COP
has been associated with radiotherapy for breast
cancer in some case reports, and it has been
defined as “radiation-primed COP” [6].
Corticosteroid treatment in COP results in rapid
clinical improvement of clinical symptoms and
clearing of the opacities on chest imaging without
sequelae. Although the efficiency of steroids in COP
has long been established, the precise dose, the
duration of treatment, the use of boluses and the
withdrawal have not been defined in radiation-
primed COP [7,8].
We report a case of COP after radiotherapy for
breast cancer, presenting with fever, dyspnea, respi-
ratory failure and bilateral pneumonia. The disease
was successfully treated with systemic steroids but
relapsed after the steroid withdrawal, and was
definitively resolved after a second steroid course.
This case emphasizes the importance of taking into
account the possible occurrence of radiation-primed
COP, and clarifies why only few women become
affected with this disease after radiotherapy,
what the optimal dose and duration of treatment
should be, and if (and, if so, which) respiratory
function tests can predict this complication.
CASE REPORT
A 62-year-old woman was admitted to our out -
patient clinic with a 2-week history of fever, dyspnea
and dry cough. Her chest radiography revealed
pneumonia in the left lower lobe, already treated
with antibiotics without benefit. She had undergone
left mastectomy 1 year earlier, and subsequent
adjuvant radiation treatment after the surgery for 50
days. In addition, immediately after the surgical
procedure she had been given therapy with anastro-
zole (Arimidex©), that was still in course at the onset
of symptoms. Computerized tomography (CT) scan
showed a pulmonary infiltration with ground glass
opacities in the left lower lobe outside the irradia-
tion fields, diagnosed as pneumonia (Figure 1).
Biochemical analysis revealed no abnormalities,
except for elevated levels of C-reactive protein
(CRP) (18 mg/dl), and the arterial blood gas analysis
showed a mild hypoxemia (PaO2 68 mm Hg, PaCO2
31 mm Hg, pH 7.43, FiO2 21%).
The initial treatment was based on antibiotics for
the clinical diagnosis of pneumonia, but clinical
symptoms of dry cough and dyspnea persisted.
Given the ineffectiveness of prolonged antibiotic
therapy, a fiberoptic bronchoscopy was performed
with bronchoalveolar lavage (BAL) and trans-
bronchial biopsy (TBBx). The BAL fluid revealed a
mild lymphocytic alveolitis (total cell count:
840/µL; lymphocytes: 15%; macrophages 84%;
neutrophils 1%; CD4+/CD8+ T-lymphocyte ratio:
1.1). TBBx was not diagnostic, and no malignant
cells or pathogenic bacteria were discovered in the
BAL fluid. Pulmonary function tests showed a mild
restrictive defect with reduction of CO-transfer:
forced vital capacity (FVC) 82% of predicted value
(pred.), forced expiratory volume in 1 sec (FEV1)
78% pred., lung diffusion capacity for carbon
monoxide (DLCO) 67% pred., KCO 82% pred.
Based on clinical, radiographic and laboratory data,
radiation-primed COP was diagnosed and a treat-
ment with systemic steroids was started at the dose
of 1 mg/kg of body weight with tapering to half dose
every 4 weeks (total duration of treatment 22
weeks). The CT scan, pulmonary function tests,
blood gas analysis and CRP at 12 weeks after the
start of steroids were all normalized.
Four weeks after steroid withdrawal, the patient
began to complain again of dry cough and dyspnea.
A new CT scan revealed newly formed opacities in
the upper right and in the middle lobes (Figure 2).
The patient underwent an identical treatment with
systemic steroids, that resulted in an immediate
improvement of symptoms, that persisted after 6
and 12 months. A complete normalization of CT
images, pulmonary function tests (FVC 94% pred.,
FEV1 90% pred., DLCO 84% pred., KCO 92% pred.),
CRP value (0.5 mg/dl) and blood gas analysis (PaO2
72 mm Hg, PaCO2 39 mm Hg, pH 7.40, FiO2 21%)
was present at 12 months of follow up.
FIGURE 1: COMPUTERIZED TOMOGRAPHY (CT) SCAN AT
FIRST OCCURRENCE OF SYMPTOMS































Reports of COP related to radiotherapy in breast
cancer,  in the form of case reports or literature
analysis [9,10], date back to 15 years ago. COP is
very similar to radiation pneumonia, but it involves
lung segments that are far from the radiation field.
Patients who undergo radiation therapy to the breast
may present alveolar lymphocytosis, even if they do
not develop pneumonia. The negative effects of
radiotherapy are well documented in the literature
(Table 1), but the histological and clinical pattern of
radiation-primed COP in the lung seems to depict a
distinct entity, with the epidemiological data, diag-
nostic and therapeutic algorithm not well defined yet.
The prevalence of radiation-primed COP ranges
between 2.5% and 1.8% [11-13], but, to our
knowledge, there are no Italian or more local data
available, that could be very useful to clarify the
influence of differences in radiation method, dos-
ing, and collimation on the occurrence of this pul-
monary complication.
The primary role of pleural factors has been
described in one sole report [9] but not confirmed
in an analysis of the recent literature [8]. Currently,
an immunological mechanism is thought to be at
the base of the disease development, as in hyper-
sensitivity pneumonitis: irradiation provokes a tis-
sue damage with sensitization of autoreactive lym-
phocytes, which react with pulmonary tissues [14].
However, it is also possible that lymphocytes are
not the key cells in the pathogenesis of radiation
primed COP; mast-cells could play a role, as in
idiopathic COP and hypersensitivity pneumonia
caused by inhaled antigens [15]. In addition, some
studies [16] have shown that radiotherapy induces
gene activation and transcription, cytokine release
and fibroblasts activation. The cause of the migrato-
ry pattern and involvement of lung tissue away from
the radiation fields remains unclear. 
Therefore, the role of diagnostic methods like
bronchoscopy with BAL appears essential and well
defined to identify the alveolar pattern of lung
involvement. Not equally defined is the role of
TBBx, because a specific histological pattern has
never been reported. From a clinical point of view,
we limited the invasive procedures to TBBx due to
the first result of absence of malignant cells or spe-
cific bacterial results, and the fast response to treat-
ment.
Considering how many women undergo surgery
and radiotherapy for breast cancer, radiation-
primed COP is not so common, and probably dif-
ferent individual elements and/or factors related to
the dose and length of radiation therapy are impli-
cated in the occurrence and progression of this pul-
monary complication. 
A general review of the literature by Cordier [8]
shows that the modifications of pulmonary function
tests are generally mild or moderate, frequently
consisting in a restrictive defect, even if an obstruc-
tive pattern can be present in patients with smoking
habit or affected by chronic obstructive pulmonary
disease. However, since the second half of the
1980s no report has clarified the changes of lung
volume, blood gas analysis or CO-transfer factor
during COP, nor the possible risk patterns of lung
damage detectable before the breast surgery and 
TABLE I: SYNOPSIS OF THE LITERATURE ON COLLATERAL EFFECTS OF RADIOTHERAPY
Lung Pneumonia 1-3 months (acute) 30 Gy Mosvas et al. Chest 1997;111:1061
12-15 months (late)
Necrosis 12 months (1-7 years > 60 Gy
for cavitations)
Pneumothorax 16 months > 30 Gy Penniment et al. Thorax 1994;49:936
Breast COP 6 wk to 10 months no minimal Crestani et al. ERJ 1995;8:318
dose defined
Lymph nodes Calcifications 12 months no minimal Bereton et al. Radiology 1974;112:705
dose defined
Esophagus Stricture 3-18 months 60 Gy Lepke et al. Radiology 1993;148:375
Vascular tree Stenosis or occlusion 10-15 years Aorta and pulm. Fajardo et al. Pathol Ann 1988;23:297
artery 24-44 Gy
Subclavian 40-60 Gy
Heart Coronary artery 10-15 years > 30 Gy age < 20 Kopelson et al. Int J Radiat Oncol Biol 
disease Phys 1978;4:895
Pericarditis 12-48 months 40 Gy Applefeld et al. Ann Intern Med 
1981;94:338
Conduction 10 years 40 Gy Cohen et al. Arch Intern Med 
abnormalities 1981;141:676
Chest wall Sarcoma > 5 years no minimal Libshitz Semin Roent 1994;29:15
dose defined
Rib fractures > 12 years 50 Gy Pierce et al. Int J Radiat Oncol Biol 
Phys 1992;23:915
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radiotherapy. 
Katayama et al. [17] showed a relation between
radiation-primed COP and hormone therapy with
tamoxifen, anastrozole and toremifen, reporting a
significant association (OR 3.12, 95% CI 1.12-8.68,
p = 0.03). Our patient received anastrozole, but it
was interrupted at the first occurrence of respiratory
symptoms. However, it is rather difficult to precisely
determine the influence of the withdrawal of this
drug on the occurrence of the pulmonary complica-
tion, and alternatively on the outcome of the breast
cancer. 
It seems really important to know which drugs rep-
resent a real risk factor for this complication, when
they are able to exert a significant role and why this
disease occurs in only few patients, with a reported
greater incidence in subjects aged more than 50
years [17]. 
In radiation-primed COP, as in other unknown dis-
eases, therapy with systemic steroids is effective
even if relapses are described after withdrawal [6].
The doses of systemic steroids range from 0.5 to 1
mg/kg of body weight a day, but due to the serious
unwanted effects of these drugs, like diabetes and
osteoporosis, especially in elderly women, the liter-
ature is not updated about the lowest effective dose
that can be used and the timing of dose tapering.
This case report shows a postmenopausal woman
submitted to surgery and radiotherapy and succes-
sively to hormone-therapy for breast cancer. The
patient presented symptoms of fever, dry cough and
dyspnea 4 months after radiotherapy; radiological
signs resembled pneumonia; BAL was suggestive of
lymphocytic alveolitis; all therapies were ineffec-
tive, but systemic steroids induced the complete
resolution of lung opacities and symptoms. This
case, by and large, is similar to previous case
reports.
However, to date, radiation primed COP still
remains unclear, with unknown causes, risk factors,
role and timing of non invasive diagnostic tests, e.g.
pulmonary function tests, and of invasive tests such
as bronchoscopy with BAL and TBBx, except for the
possibility of excluding a diagnosis of cancer or
tuberculosis. 
Thus, we think it would be very useful to obtain epi-
demiological data about all women undergoing sur-
gery and radiotherapy for breast cancer, to reveal
possible relationships between radiation, hormone-
therapy, and individual factors, in particular con-
cerning the respiratory function before and during
the treatment.
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